SALIOGASE Trademark Application
Summary
USPTO received trademark application TM90517616 for SALIOGASE under Class 005 (Pharmaceuticals). The application, filed as Intent to Use, covers pharmaceutical preparations for treating genetically driven, neurological, gastrointestinal, metabolic, immunological, oncological, and other specified disorders. Related goods include scientific reagents, nucleic acids, and nucleotides for research and medical purposes.
What changed
USPTO Trademark Application Serial No. TM90517616 was filed on February 8, 2021, for the mark SALIOGASE under Nice Classification 005 (Pharmaceutical Preparations). The goods and services covered include pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias, musculoskeletal, and oncological disorders, as well as diseases affecting the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney. The application also covers reagents, nucleic acids, and nucleotides for scientific, research, medical, and veterinary purposes.
This is a routine trademark application filing that does not impose compliance obligations on third parties. Trademark applicants should monitor the application status in the USPTO Trademark Status and Document Retrieval (TSDR) system. No immediate action is required from competitors or industry stakeholders unless they have conflicting marks or wish to file opposition proceedings during the publication period.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
← USPTO Trademark Applications
SALIOGASE
Intent to Use TM90517616 Kind: intenttouse Apr 02, 2026
Abstract
Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research; Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes
Filing Date
2021-02-08
Named provisions
Related changes
Get daily alerts for USPTO Trademarks - Pharmaceuticals (Class 005)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Trademarks - Pharmaceuticals (Class 005) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.